产NDM肠杆菌对氨曲南-阿维巴坦药敏试验方法的比较
该研究纳入254株产NDM肠杆菌临床分离株,以肉汤微量稀释法为参考,评估纸片扩散法和两种梯度扩散法检测氨曲南-阿维巴坦敏感性的性能。所有245株原始分离株均敏感,纸片扩散法分类一致率98%,梯度扩散法均为99%,提示扩散法可作为临床实验室的实用替代方法。
要点
- 纸片扩散法与梯度扩散法对氨曲南-阿维巴坦均有较高分类一致率。
- 梯度扩散法基本一致率偏低,倾向低估MIC值,需谨慎解读。
- 全部245株产NDM肠杆菌原始分离株对氨曲南-阿维巴坦敏感。
核心结论
- 氨曲南-阿维巴坦对产NDM肠杆菌分离株表现出稳定的体外活性。
- 纸片扩散法和梯度扩散法可作为肉汤微量稀释法的实用替代方法用于临床实验室。
研究设计与样本
- 研究纳入2022至2024年从智利和美国医院独特患者中收集的245株非重复产NDM肠杆菌分离株。
- 另加入9株来自独立收集的氨曲南-阿维巴坦非敏感分离株以富集耐药株,最终共254株。
- 以CLSI标准肉汤微量稀释法为参考,评估纸片扩散法及两种梯度扩散法(ETEST和MIC Test Strip)的分类一致率、基本一致率和CLSI定义的误差率。
主要发现
- 所有245株产NDM肠杆菌原始分离株均对氨曲南-阿维巴坦敏感(MIC ≤4/4 µg/mL),MIC₅₀/₉₀分别为0.25/4和1/4 µg/mL。
- 菌种构成比为肺炎克雷伯菌71%、阴沟肠杆菌复合群21%、大肠埃希菌8%,主要NDM等位基因为blaNDM-1和blaNDM-7。
- 纸片扩散法分类一致率为98%(250/254),出现4个次要误差。
- 两种梯度扩散法分类一致率均为99%(252/254),无极重大或重大误差,各出现2个次要误差。
- 基本一致率ETEST为67%、MIC Test Strip为85%,两种梯度扩散法均倾向于低估氨曲南-阿维巴坦MIC值。
关键数值与推荐
- 参考肉汤微量稀释法按CLSI标准执行,氨曲南-阿维巴坦敏感折点为MIC ≤4/4 µg/mL。
- 纸片扩散法分类一致率98%(250/254),次要误差4个。
- 梯度扩散法分类一致率99%(252/254),无极重大或重大误差,次要误差2个。
- 基本一致率:ETEST 67%,MIC Test Strip 85%。
临床怎么用
- 临床实验室可考虑采用纸片扩散法或梯度扩散法检测产NDM肠杆菌对氨曲南-阿维巴坦的敏感性。
- 使用梯度扩散法时需注意其可能低估MIC值,对接近折点的结果应谨慎解读。
局限性
- 研究仅纳入产NDM肠杆菌,结论外推至其他碳青霉烯酶类型需谨慎。
- 耐药分离株通过额外加入9株非敏感株富集,可能影响误差率估计的代表性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aztreonam-avibactam (ATM-AVI) is a promising therapeutic for New Delhi metallo-β-lactamase-producing Enterobacterales (NDM-E) infections. We evaluated the performance of disk diffusion and gradient diffusion methods compared with reference broth microdilution (BMD) for ATM-AVI susceptibility testing. A total of 245 non-duplicate NDM-E isolates were included, collected from unique patients at hospitals in Chile and the United States between 2022 and 2024. Nine ATM-AVI non-susceptible isolates from a separate collection were added to enrich for resistant isolates, yielding a total of 254 isolates. Reference BMD was performed according to Clinical and Laboratory Standards Institute (CLSI) criteria. ATM-AVI disk diffusion and two gradient diffusion methods (ETEST and MIC Test Strip) were evaluated against BMD using categorical agreement, essential agreement, and CLSI-defined error rates. All 245 NDM-E isolates were susceptible to ATM-AVI (MIC ≤4/4 µg/mL), with MIC₅₀/₉₀ values of 0.25/4 and 1/4 µg/mL, respectively. The collection consisted of Klebsiella pneumoniae (71%), Enterobacter cloacae complex (21%), and Escherichia coli (8%). Predominant NDM alleles included blaNDM-1 and blaNDM-7. Disk diffusion demonstrated 98% categorical agreement (250/254), with four minor errors. Both gradient diffusion methods achieved 99% categorical agreement (252/254), with no very major or major errors and two minor errors. Essential agreement was 67% for ETEST and 85% for MIC Test Strip; both methods tended to underestimate ATM-AVI MICs relative to BMD. ATM-AVI demonstrated robust in vitro activity against a contemporary NDM-E cohort. Disk and gradient diffusion methods are practical alternatives to BMD for clinical laboratories.
引用
- Rivas L, Díaz L, Quiroz V, et al. Comparison of antimicrobial susceptibility testing methods for aztreonam-avibactam against NDM-producing Enterobacterales clinical isolates. J Clin Microbiol. 2026. PMID: 42861991. doi:10.1128/jcm.00797-26
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。